Skip to main content

GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost

The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.